Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow-up.
恶性胸膜间皮瘤（MPM）是一种起源于胸膜的恶性肿瘤，近年来其发病率一直在上升。由于 MPM 的隐匿性发病和强烈的局部侵袭性，大多数患者在晚期才被诊断出来，因此对高危人群进行早期筛查和治疗至关重要。MPM 的治疗主要包括手术、化疗和放疗。免疫疗法和电场疗法也已应用，这使得患者的生存率进一步提高。长三角肺癌合作组间皮瘤专家组（华东肺癌协作组，ECLUNG；青年委员会）基于现有的临床研究证据和国内专家意见，制定了 MPM 的临床诊断和治疗的全国共识。该共识旨在促进中国 MPM 诊断和治疗的同质化和标准化，涵盖流行病学、诊断、治疗和随访。
